GURUFOCUS.COM » STOCK LIST » USA » NYSE » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Debt-to-Equity
Switch to:

Bristol-Myers Squibb Co Debt-to-Equity

: 1.32 (As of Jun. 2022)
View and export this data going back to 1952. Start your Free Trial

Bristol-Myers Squibb Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $5,120 Mil. Bristol-Myers Squibb Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $37,922 Mil. Bristol-Myers Squibb Co's Total Stockholders Equity for the quarter that ended in Jun. 2022 was $32,600 Mil. Bristol-Myers Squibb Co's debt to equity for the quarter that ended in Jun. 2022 was 1.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bristol-Myers Squibb Co's Debt-to-Equity or its related term are showing as below:

BMY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08   Med: 0.47   Max: 1.56
Current: 1.32

During the past 13 years, the highest Debt-to-Equity Ratio of Bristol-Myers Squibb Co was 1.56. The lowest was 0.08. And the median was 0.47.

BMY's Debt-to-Equity is ranked worse than
88.93% of 858 companies
in the Drug Manufacturers industry
Industry Median: 0.30 vs BMY: 1.32

Bristol-Myers Squibb Co Debt-to-Equity Historical Data

The historical data trend for Bristol-Myers Squibb Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.52 0.92 1.37 1.27

Bristol-Myers Squibb Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.26 1.23 1.27 1.46 1.32

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Bristol-Myers Squibb Co Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Debt-to-Equity falls into.



Bristol-Myers Squibb Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bristol-Myers Squibb Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Bristol-Myers Squibb Co's Debt to Equity Ratio for the quarter that ended in Jun. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co  (NYSE:BMY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Bristol-Myers Squibb Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Bristol-Myers Squibb Co logo
Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Executives
Greenlees Sharon officer: SVP & Controller BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Shanahan Karin officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Meyers Gregory Scott officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Weese Michelle officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Hidalgo Medina Manuel director BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016
Rice Derica W director 1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403
Price Paula A director ONE CVS DRIVE WOONSOCKET RI 02895
Mily Elizabeth officer: EVP, Strategy & BD BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540
Metcalfe Kathryn officer: EVP, Corporate Affairs BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Vessey Rupert officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Elkins David V officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417
Bonney Michael W director 65 HAYDEN AVE LEXINGTON MA 02421
Yale Phyllis R director
Ahmed Nadim officer: President, Hematology C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Haller Julia A director C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901

Bristol-Myers Squibb Co Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)